Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome

  • Medtech innovation briefing
  • MIB223
  • Published: 
Download (PDF)

Regulatory information

Spartan RX is CE marked as a class I in vitro diagnostic.